

**Joint working executive summary**

<p><b>Project title</b></p>	<p>A Joint working agreement between Sanofi and The Christie NHS Foundation Trust to understand and improve the patient journey and experience within the cSCC service across Greater Manchester</p>
<p><b>Partner organisation/s</b></p>	<p>The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX</p> <p>Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT</p>
<p><b>Project rationale</b></p>	<p>Pressures from an increasing incidence, case complexity and survivorship, as outlined below, are impacting greatly on the management of cSCC patients.</p> <ul style="list-style-type: none"> <li>• <b>Increasing incidence:</b> The worldwide incidence of cSCC is increasing (36% increase in the UK between 2000 and 2010<sup>1</sup>).</li> <li>1. <b>Increasing case complexity:</b> We are seeing increasing number of patients with complex management problems (transplant patients, immunocompromised patients and elderly patients with multiple comorbidities).</li> <li>• <b>Increasing survivorship and prevalence with new therapies:</b> The department have now treated over 30 patients with newer agents and each week this is approximately 1/3 of the clinic (between 6 – 10 patients weekly) so this patient group will continue to grow.</li> <li>• <b>Treatment Intervention:</b> Treatment intervention has been shown to be most effective when given early in patients disease process and before the cancer has spread to an irreversible situation</li> </ul> <p>These pressures along with the impact of the Covid pandemic have emphasised the need to look at the way the cSCC service currently runs within Greater Manchester along with the current patient pathway in order to future proof the service and pathway to ensure that it is fit for purpose and is sustainable in the future.</p> <p>Based on the above, the lead team within the Oncology department at the Christie NHS Foundation trust have approached Sanofi requesting support to partner with them on an innovative pilot to review the current service provision, referral pathway and trust pathway to understand the current challenges and pressure points within the service. To deliver on these work streams, the Christie are requesting support from Sanofi in terms of additional cSCC CNS resource along with Project management</p>

	<p>support to help in the implementation of this project. The key aspects of this project will include:</p> <ul style="list-style-type: none"> <li>• Regional and National leadership and service development</li> <li>• Educational support for patients and HCPs</li> <li>• Expanding the cSCC CNS role</li> </ul>
<p><b>Project period</b></p>	<p>Q4 2021- Q1 2024</p>
<p><b>Project objectives</b></p>	<p><b>Patients:</b></p> <p>Patients might expect more equitable and consistent care as well as improved and quicker access to care, better education around cSCC, better access to treatment options as well as a clearer pathway of care with a better experience of the system.</p> <p><b>Hospital Trust / local CCGs:</b></p> <p>Better and more efficient patient pathway for cSCC across the Greater Manchester area</p> <p>Reduced wait times to be seen by a specialised clinician</p> <p>Potentially, Increased number of patients identified and referred, assessed and potentially initiated on treatment in a more timely manner</p> <p>Better understanding and knowledge of cSCC among local HCPs</p> <p>Increased engagements with appropriate patients to provide additional support and education</p> <p><b>Sanofi:</b></p> <p>A better understanding of the cSCC service and pathway across the Greater Manchester area</p> <p>Greater understanding of the needs of the NHS customer in cSCC</p> <p>Improved reputation within Oncology through partnering with the Christie NHS Foundation trust and the other relevant NHS organisations across Greater Manchester</p> <p>The following outcome measures will be used to assess the impact of this project:</p> <ul style="list-style-type: none"> <li>• <b>Outcome measure 1, supporting the cSCC referral pathway across the region</b> <ul style="list-style-type: none"> <li>• Number of patients being identified with cSCC.</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>• Once identified, the waiting time for a patient to be seen by the Specialist team.</li> <li>• The time which a patient is spending in the pathway.</li> <li>• If appropriate, waiting time for patients to be prescribed and initiated on SACT therapy.</li> <li>• <b>Outcome Measure 2, supporting national cSCC service across the NHS in England</b> <ul style="list-style-type: none"> <li>• Number of education sessions that are delivered by the CNS to local/national HCPs</li> <li>• Delivery of protocols for CNS role and additional nurse led support across the catchment area</li> </ul> </li> <li>• <b>Outcome Measure 3, supporting patients receiving systemic therapy</b> <ul style="list-style-type: none"> <li>• Patient co-morbidities and frailty assessment scores</li> <li>• Number of patient queries that been raised (and solved)</li> <li>• Patient satisfaction based on their service experience</li> </ul> </li> </ul>
<p><b>Contact details</b></p>	<p>Dr Robert Metcalf, Clinical Oncology Consultant, The Christie NHS Foundation Trust</p> <p><a href="mailto:robert.metcalf1@nhs.net">robert.metcalf1@nhs.net</a></p> <p>Fleur Chandler, Director of Market Access, Sanofi</p> <p><a href="mailto:GB-MarketAccess@sanofi.com">GB-MarketAccess@sanofi.com</a></p>